(Q55070705)

English

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

scientific article published in January 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

1 reference

based on heuristic

inferred from title

alopecia universalis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

Paola Guglielmelli

2

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

author name string

Alessandro M Vannucchi

3

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

90

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

1

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

82-83

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23871

21 January 2018

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23871

21 January 2018

From palliation to targeted therapy in myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23871

21 January 2018

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23871

21 January 2018

Identifiers

10.1002/AJH.23871

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 June 2018

http://europepmc.org/abstract/MED/25307179

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55070705&oldid=1525242217"